Boston healthcare deals involve more regulatory bodies than almost any other market in the country. The Massachusetts Determination of Need program, the Corporate Practice of Medicine framework, the Attorney General's Non-Profit Organizations Division for certain transactions, and layered licensing across specialty services all apply before the purchase agreement matters. Our managing partner handles healthcare acquisition engagements directly. Submit the transaction details if you have a qualified target.
Share the basics. Alex reviews every inquiry personally.
Your transaction details are under review. If there is alignment, we will be in touch.
Meanwhile, feel free to call us directly at (248) 266-2790
Alex Lubyansky handles healthcare m&a legal services work for buyers and sellers in Boston and across the country. Here is what that looks like:
We work best with people who know what they want and are ready to move:
Tell us what you are working on. We respond within one business day.
Your transaction details are under review. If there is alignment, we will be in touch.
Meanwhile, feel free to call us directly at (248) 266-2790
A structured, methodical approach to healthcare m&a legal services
We map the state-specific regulatory path for your transaction, including CON requirements, CPOM posture, AG review triggers, and provider number transfer mechanics before any term sheet is signed.
Managing Partner Alex Lubyansky leads diligence across payor contracts, Medicare and Medicaid enrollment, Stark and AKS exposure, HIPAA posture, licensure, and compliance program maturity to surface deal risks early.
We structure the deal to respect CPOM limits, optimize tax and liability treatment, and, where needed, design MSO or friendly-PC arrangements that preserve clinical independence and protect the economic deal.
We negotiate the purchase agreement, ancillary documents, and transition services agreement while coordinating CON filings, AG notifications, payor consents, and CHOW applications on a closing-driven timeline.
We manage closing logistics, provider number transitions, and post-closing integration items so patient care, billing, and payor reimbursement continue without disruption.
We don't take every matter. Here is what happens when you reach out.
Alex reviews your transaction details personally. No intake coordinators, no junior associates screening your submission.
We evaluate whether your deal aligns with our practice. Not every matter is a fit, and we will tell you directly if it is not.
If there is alignment, Alex schedules a direct call to discuss your transaction, timeline, and objectives.
Before any work begins, you receive a written engagement letter with defined scope, timeline, and fee structure. No surprises.
Alex Lubyansky handles every healthcare m&a legal services engagement personally.
15+ years of M&A experience. Nationwide. One attorney on every deal.
We review every transaction inquiry within one business day.
Your transaction details are under review. If there is alignment, we will be in touch.
Meanwhile, feel free to call us directly at (248) 266-2790
Use these before you call any firm, including ours.
At many firms, a partner sells the work and a junior associate does it. Ask for the name of the attorney who will draft and negotiate your documents.
Volume indicates current, active deal experience, not just credentials from years ago.
A $500K SBA acquisition and a $50M PE deal require different skill sets. Make sure the attorney has handled transactions similar to yours.
M&A transactions require a team. Your attorney should work with your other advisors, not in a silo.
Reps, warranties, and indemnification claims surface months after closing. Ask whether the firm handles post-closing litigation or refers it out.
Hourly, flat fee, or hybrid. Ask what factors increase legal costs so there are no surprises.
Common questions from Boston clients
Submit your transaction details for a preliminary assessment by our managing partner
Submit Transaction DetailsSubmit transaction details and Alex will respond directly.
Your transaction details are under review. If there is alignment, we will be in touch.
Meanwhile, feel free to call us directly at (248) 266-2790
Boston is the global epicenter of biotech and life sciences M&A, with Kendall Square and the Route 128 corridor housing the densest concentration of biotech companies outside San Francisco. Beyond life sciences, the region drives significant deal activity in financial technology, education technology, and defense contracting. The region's deep research university ecosystem (MIT, Harvard, Tufts) produces a steady stream of spinoff companies ripe for acquisition.
Boston's biotech-heavy deal market means acquirers often face complex IP due diligence involving university licenses, clinical trial data, and FDA regulatory considerations. Competition from large pharma strategic acquirers can push valuations higher for promising targets.
Boston's concentration of world-class research institutions and highly educated workforce creates a self-reinforcing ecosystem where acquired companies can access talent, partnerships, and capital unavailable in other markets.
Massachusetts enacted the Noncompetition Agreement Act in 2018, limiting non-competes to 12 months and requiring garden leave pay - buyers must evaluate existing employee agreements during due diligence as many pre-2018 agreements may now be unenforceable.
We specialize in biotech and life sciences securities transactions, understanding the unique regulatory and scientific complexities of this sector.
Massachusetts runs the Determination of Need program through the Department of Public Health, which functions as the state's Certificate of Need equivalent. DoN review applies to certain facility construction, service expansions, and equipment acquisitions above statutory thresholds. Many ambulatory and specialty service acquisitions also intersect with DoN review, and timelines for DoN can be measured in months. Massachusetts also enforces Corporate Practice of Medicine rules strongly, making MSO structuring essential for non-physician investors. For non-profit targets, the Attorney General's Non-Profit Organizations Division reviews change-of-control transactions to protect charitable assets, and that review can be substantial. Boston's academic medical centers and teaching hospital affiliations produce specialty practice deal flow with specific payor and referral dynamics, and buyers in this market run diligence at Harvard-teaching-hospital standards.
Many Massachusetts ambulatory and specialty services acquisitions trigger Determination of Need review with the Department of Public Health. The DoN process has defined timelines, public comment periods, and substantive standards. Purchase agreements need closing conditions tied to DoN approval, with defined outside dates and walk rights on both sides if approval is delayed or denied.
Massachusetts enforces CPOM strictly, so non-physician buyers use MSO structures. The physician-owned professional entity practices medicine; the MSO provides management services. Massachusetts regulators scrutinize MSO structures more carefully than some states, and fee-splitting and control provisions have to be drafted with attention to state-specific case law.
Acquisitions involving Massachusetts non-profit healthcare entities trigger review by the Attorney General's Non-Profit Organizations Division, which examines whether the transaction preserves charitable assets and whether the transaction serves the charitable mission. AG review can produce material conditions and may require changes to deal terms.
Boston's healthcare M&A market is shaped by concentrated academic medical center activity, a strong regulatory framework, and deal structures that reflect Massachusetts-specific rules on DoN, CPOM, and non-profit asset protection. Buyers who plan for DoN timelines, structure MSOs with Massachusetts-specific attention, and build AG review into the deal schedule for non-profit targets close on predictable paths. Buyers who treat Boston like a lighter-regulated market get surprised.
Restricted with 12-month cap and garden leave requirement. Sale-of-business exception.
Entity mergers and conversions require filing with the Massachusetts Secretary of the Commonwealth, Corporations Division. The Department of Revenue requires tax waivers for asset purchases. Professional corporations require additional filings with the relevant licensing board.
In-depth guides to help you prepare for your transaction
Full-service M&A counsel from letter of intent through closing.
Read guideA structured approach to legal, financial, and operational due diligence.
Read guideUnderstanding the binding and non-binding elements of each document.
Read guideCommon deal-killers and how experienced counsel helps prevent them.
Read guide
"Healthcare acquisitions require a second layer of diligence most deals don't. Stark, Anti-Kickback, state licensure, corporate practice of medicine, payor contracts. Miss any of them and you've bought a compliance problem instead of a practice."
15+ years of M&A and securities transaction experience Senior counsel on every engagement Admitted in Michigan, practicing nationwide
Reviewed by Alex Lubyansky on . Read full bio
Alex Lubyansky handles every engagement personally. Tell us about your transaction and we will let you know if there is a fit.
Tell us about your deal. We review every submission and respond within one business day.
Your transaction details are under review. If there is alignment, we will be in touch.
Meanwhile, feel free to call us directly at (248) 266-2790
One attorney on every deal. Nationwide. 15+ years of M&A experience.